FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Active, not recruiting · NCT05077800 · Registry updated 2026-09-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer | pancreatic adenocarcinoma | Active, not recruiting | Phase 2 | 2026-09-11 | NCT05077800 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Actuate Therapeutics Inc. | 5 |
| Colin D. Weekes, M.D., PhD | 1 |
| Lustgarten Foundation | 12 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Massachusetts General Hospital | Charlestown | United States | 22 |
| Massachusetts General Hospital Cancer Center | Boston | United States | 178 |
| University of Colorado Cancer Center | Aurora | United States | 63 |
| University of Washington School of Medicine | Seattle | United States | 4 |